Skip to content

The real world study of pyrotinib in the treatment of HER2 positive early breast cancer

The real world study of pyrotinib in the treatment of HER2 positive early breast cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070206
Enrollment
Unknown
Registered
2023-04-04
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group of breast cancer (pyrotinib and other drugs selected by the doctors):None

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; 2. Early breast cancer patients diagnosed as HER2 positive by pathology or histocytology; 3. Plan to receive pyrotinib for neoadjuvant or adjuvant treatment; 4. Have a traceable medical history during treatment; 5. Meet any of the following high-risk conditions: (1) Patients who plan to use pyrotinib for neoadjuvant treatment after 4 cycles of neoadjuvant treatment without pyrotinib and whose tumors have shrunk by <= 50%; (2) Patients who have not obtained pCR after completing a previous neoadjuvant treatment without pyrotinib; (3) Patients with positive axillary lymph nodes in stage II to stage IIIc, according to the breast cancer staging criteria of the American Joint Commission on Cancer (8th edition), (Isolated tumor cells and micrometastasis are respectively considered as pN0 and pN1). Patients who have completed neoadjuvant treatment and only have residual invasive cancer in the breast but have negative lymph nodes or unknown lymph node status are eligible.

Exclusion criteria

Exclusion criteria: 1. Have received neoadjuvant treatment and obtained pCR; 2. Unsigned informed consent form; 3. Pregnant or lactating women; 4. Other situations judged by the researcher not suitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Pathological Complete Remission, ORR;Invasive Disease-free Survival, iDFS;

Secondary

MeasureTime frame
Overall Survival, OS;Objective Response Rate, ORR;Progression-Free-Survival, PFS;Time-To-Progression;Clinical Benefit Rate, CBR;Duration of Response, DoR;Safety;Adverse events and Serious adverse events;

Countries

China

Contacts

Public ContactQiang Liu

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

victorlq@hotmail.com+86 13922251256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026